Financial comparisons Immix Biopharma, Inc.
Equities
IMMX
US45258H1068
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.730 USD | +1.97% |
|
+62.17% | +205.91% |
| Dec. 07 | Immix Biopharma prices offering of 19.1 million shares at $5.10 per share | RE |
| Nov. 12 | Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer | CI |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 2.22B | 36.99% | -0.96% | 2.26% | 2.02% | 818.71x | |
| 364M | -251.24% | -241.47% | -1,601.19% | -54.47% | 0.16x | |
| 5.38B | 24.08% | 29.51% | 16.78% | 12.27% | -0.97x | |
| 2.85B | -24.18% | -47.77% | -3.3% | -2.88% | 9.36x | |
| 2.99B | 36.44% | 32.53% | 22.97% | 19.34% | -2.97x | |
| 2.56B | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | |
| 291M | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | |
| 265M | -13.8% | -7.18% | -9.46% | -9.11% | 18.95x | |
| 180M | -258.64% | -276.39% | -80.35% | - | 1.63x | |
| 2.17B | 24.04% | 27.88% | 23.13% | 17.7% | -1.75x | |
| 829M | -0.2% | 11.86% | -0.5% | - | -6.61x | |
| 18.47M | -3,191.11% | -2,902.72% | - | -52.97% | 0.77x | |
| 36.13M | -595.93% | -752.96% | -42.88% | - | 1.96x | |
| Average | 1.55B | -324.6% | -317.58% | -139.15% | -6.44% | 64.29x | |
| Weighted average by Cap. | 2.06B | -143.9% | -147.37% | -252.38% | -6.61% | 166.92x |
- Stock Market
- Equities
- IMMX Stock
- Sector Immix Biopharma, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
